Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2016 07:05 ET | Source: Advaxis

Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort

Study Commences Second Dose-Escalation Cohort 90-Patient Phase II Combination Trial in Cervical and Head and Neck Cancer to Begin Mid-Year PRINCETON, N.J., March 29, 2016 (GLOBE NEWSWIRE) --...
March 23, 2016 08:08 ET | Source: Advaxis

UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract

PRINCETON, N.J., March 23, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host...
March 23, 2016 07:05 ET | Source: Advaxis

Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract

PRINCETON, N.J., March 23, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host...
March 21, 2016 07:05 ET | Source: Advaxis

Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research

PRINCETON, N.J., March 21, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a...
March 14, 2016 09:05 ET | Source: Advaxis

Advaxis to Present at Barclays Global Healthcare Conference

PRINCETON, N.J., March 14, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it is scheduled to...
March 11, 2016 09:05 ET | Source: Advaxis

Advaxis Elects Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors

PRINCETON, N.J., March 11, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Gregory Mayes,...
March 09, 2016 07:05 ET | Source: Advaxis

Advaxis Truly Personalized Cancer Immunotherapy Moves Forward With Signing of an Exclusive Supply Agreement With Synthetic Genomics for Synthetic DNA

PRINCETON, N.J., March 09, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, and SGI-DNA, a wholly owned subsidiary of...
March 07, 2016 07:05 ET | Source: Advaxis

Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer

PRINCETON, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced dose administration for...
March 04, 2016 09:05 ET | Source: Advaxis

Advaxis to Present at 27th Annual ROTH Conference

PRINCETON, N.J., March 04, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, announced today that Gregory Mayes,...
March 02, 2016 07:05 ET | Source: Advaxis

Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting

PRINCETON, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a Phase 2...